Investing.comDoubao · 实盘不做把握 5/10不做原因:风险收益比不佳
北京时间·🕒 发布 04:14:32·⟳ 抓取 04:15:56 +1m24s·⚡ 决策 10-21 04:26:42 +10m46s·6.8 天前
直觉外科Q3调整后EPS与营收双超预期、手术量增长约15%，但反垄断和解一次性费用叠加指引偏软，盘后一度暴跌约13%
方向上这是一次‘超预期但被抛售’的财报：调整后EPS/营收双超预期、手术量+15%、装机+12%并大举回购29.4亿美元，核心经营并未恶化，不满足强做空催化（无指引下修、无需求恶化、费用为一次性）；但唯一高对齐先例（同公司Q2 2026）显示在‘市场以手术量增速而非EPS超预期定价’的regime下，强劲财报后股价仍在5个交易日内下跌约17%，左侧做多等于接刀。盘后已实时下跌约10.6%（一度-13%），可比先例约-14%的首日跌幅大部分已兑现，剩余下行空间相对‘$29.4亿回购托底+股价已处52周低位附近+超卖反弹’的逼空/反弹风险并不划算，多空两侧均无正期望edge，故不做。
📄 原文Investing.com↗ 原文
Intuitive Surgical slides 13% as earnings hit by pre-tax charge
SUNNYVALE, Calif. - Intuitive Surgical Inc. (NASDAQ:ISRG) reported third quarter results that exceeded Wall Street expe…
不做 Intuitive Surgical（ISRG.US）
多空双避：核心经营强劲（营收+22%、调整后EPS超预期、手术量+15%、Q3回购$29.4亿、一次性和解费），不满足强做空催化；但同公司Q2‘beat仍被抛售’先例5日跌约17%且当前市场以手术量增速定价，左侧做多接刀风险大；盘后已实时下跌约10.6%，可比首日跌幅大部分兑现，残余下行相对回购托底+近52周低位的超卖反弹风险不具正期望。等次日常规时段方向明朗（续跌企稳或放量收复盘后跌幅）后再评估。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
ISRG Q3调整后业绩双超预期、手术量+15%并大举回购，但$4.5亿一次性和解费与含关税的偏软指引触发盘后约-11%抛售；强基本面+回购托底不支持做空，而同公司Q2‘beat仍被抛售’5日跌约17%的先例不支持左侧抄底，盘后已跌掉大部分可比幅度，风险回报不成立。
消息传播链
- 公司盘后官方发布Q3财报，含$4.5亿反垄断和解费用、14-15%手术量指引及Q3回购$29.4亿市场反应:盘后随即下挫
- AI辅助生成、编辑审核的快讯报道股价下挫13.2%，强调一次性费用冲击市场反应:盘后约-10.6%至$391.45，低点$378，放量41.16万股
关键理由
- 做空不成立的核心：营收+22%、调整后EPS超预期$0.35、手术量+15%、Q3回购$29.4亿，GAAP miss主要来自一次性$4.5亿和解费，无指引下修或需求恶化
- 做多不成立的核心：当前市场对ISRG以手术量增速而非EPS超预期定价，Q2同regime先例5日跌约17%，且盘后仅兑现约-11%、可能仍有余波
主要风险
- 若把它当动量做空：盘后已-10.6%且股价距52周低$328.57仅约19%，$29.4亿回购与超卖状态可能引发强劲relief rally，Barchart亦提示分析师下调后接近超卖反弹区
- 若把它当抄底做多：Q2 2026对齐先例首反应日-14%、第5日-17.5%且无快速V型修复，接刀可能继续浮亏
反向证据
- 做空前查反向 · 来源 web · 日期 2026-10-20 · 影响 weakens
反向证据强：营收+22%、EPS超预期、手术量+15%、Ion+31%、装机+12%、Q3回购$29.4亿，且费用为一次性、指引仅维持未下修
检索:Intuitive Surgical Q3 2026 guidance raised buyback procedure growth positive 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-07-18 · 影响 weakens
同公司Q2强劲季报后股价当周大跌、event_study显示5日-17.5%，‘超预期不涨反跌’regime明确
检索:Intuitive Surgical strong quarter still spooked investors Q2 2026 stock drop 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例使我们排除做多（接刀风险），但因本次无指引下修、含一次性费用且有$29.4亿回购、股价已近52周低，强做空催化与入场点位均不满足，最终多空双避
方向:唯一对齐先例（相似度7、未达8分clean门槛）方向明确偏负：强劲财报后+1/-3/-5日分别约-14%/-13%/-17%，胜率0/1，但样本仅1条且置信区间很宽
涨幅量级:因clean_n=0、样本very_thin，不能用其-14%/-17%精确设定tp/sl；仅提示盘后约-11%后次日常规时段仍可能有残余下行
形态:该先例为缺口低开、盘中续跌，第2日小幅反抽后第3-5日再创新低，非快速见光死V型修复，抑制左侧做多
历史先例(按相似度)
- 相似度 7/10 ISRG 2026-07-16 Q2 2026强劲季报但指引偏软，7/17自$402.33缺口低开至$365、收$345.42（-14.2%），随后5日累计约-17.5% 原文 ↗
事件后 +1日 -14.2% · +2日 -12.2% · +3日 -13.0% · +4日 -15.3% · +5日 -17.5%
⚠来源层级不符(声明issuer/实为media)·未核对目标相位 — 该行涨幅别用来定止盈止损
相似度依据:同一家公司、同为盘后财报、同样是‘营收利润强劲但指引/手术量未加速而吓跑投资者’的regime，差异在于本次额外含一次性和解费
经验:在市场以手术量增速而非EPS超预期定价的阶段，ISRG业绩超预期仍会被持续抛售，首反应日缺口低开后5日继续走弱，不宜左侧接刀
工具执行结果 · 成功 5 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 12 ms
{"result": "search_processed_events:agent query=`intuitive surgical isrg q3 2026 earnings antitrust settlement charge $450 million | 直觉外科 isrg 三季报 反垄断和解 费用 跌13%`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - stock_quote 成功 stock_tools HTTP · 86 ms
{ - web_search 成功 doubao_search · 1,107 ms
豆包搜索结果（原始查询:Intuitive Surgical ISRG Q3 2026 earnings stock drop guidance reaction analysts；API SearchType:web） - web_search 成功 doubao_search · 1,585 ms
豆包搜索结果（原始查询:Intuitive Surgical antitrust class action settlement $450 million Q3 2026 details；API SearchType:web） - event_study 成功 stock_tools HTTP · 16 ms
{
原文全文
展开原文 · 1,959 字
SUNNYVALE, Calif. - Intuitive Surgical Inc. (NASDAQ:ISRG) reported third quarter results that exceeded Wall Street expectations, yet shares tumbled 13.2%
The robotic surgery pioneer posted adjusted earnings per share of $3.00, beating the analyst consensus of $2.65 by $0.35. Revenue reached $3.05 billion, up 22% from $2.51 billion in the year-ago quarter and surpassing the $2.91 billion analyst estimate.
Intuitive guided full-year da Vinci procedure growth of 14% to 15%, with management expecting results closer to the midpoint of that range. The company also projected adjusted gross profit margin of 68.7% to 69.3% of revenue, which includes an estimated 0.9% impact from tariffs. Adjusted operating expense growth is expected at 11% to 13% for the year.
The quarter’s GAAP earnings of $1.49 per share were significantly impacted by a $450 million pre-tax charge related to the settlement of antitrust class action litigation, which reduced earnings by $0.99 per share. Excluding this charge and other items, adjusted net income was $1.05 billion, up from $867 million in the third quarter of 2025.
"Our strong performance this quarter was marked by broad-based adoption across our multi-port, single-port, and Ion platforms, with customers using our systems to perform, on average, over 10,000 procedures per day throughout the period," said Dave Rosa, Intuitive CEO.
The company placed 546 da Vinci surgical systems in the quarter, including 315 da Vinci 5 systems, compared with 427 total placements in the prior-year period. Worldwide procedures grew approximately 15%, with da Vinci procedures up 14% and Ion procedures surging 31%.
Instruments and accessories revenue increased 18% to $1.80 billion, while systems revenue rose to $769 million from $590 million. The company’s installed base reached 12,094 da Vinci systems, up 12% YoY.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The robotic surgery pioneer posted adjusted earnings per share of $3.00, beating the analyst consensus of $2.65 by $0.35. Revenue reached $3.05 billion, up 22% from $2.51 billion in the year-ago quarter and surpassing the $2.91 billion analyst estimate.
Intuitive guided full-year da Vinci procedure growth of 14% to 15%, with management expecting results closer to the midpoint of that range. The company also projected adjusted gross profit margin of 68.7% to 69.3% of revenue, which includes an estimated 0.9% impact from tariffs. Adjusted operating expense growth is expected at 11% to 13% for the year.
The quarter’s GAAP earnings of $1.49 per share were significantly impacted by a $450 million pre-tax charge related to the settlement of antitrust class action litigation, which reduced earnings by $0.99 per share. Excluding this charge and other items, adjusted net income was $1.05 billion, up from $867 million in the third quarter of 2025.
"Our strong performance this quarter was marked by broad-based adoption across our multi-port, single-port, and Ion platforms, with customers using our systems to perform, on average, over 10,000 procedures per day throughout the period," said Dave Rosa, Intuitive CEO.
The company placed 546 da Vinci surgical systems in the quarter, including 315 da Vinci 5 systems, compared with 427 total placements in the prior-year period. Worldwide procedures grew approximately 15%, with da Vinci procedures up 14% and Ion procedures surging 31%.
Instruments and accessories revenue increased 18% to $1.80 billion, while systems revenue rose to $769 million from $590 million. The company’s installed base reached 12,094 da Vinci systems, up 12% YoY.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
f94b4d3bac· 2026-10-21 04:26 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前